Wellcome Trust establishes first Translational Partnership in Germany – with the BIH and Charité

Wellcome Trust establishes first Translational Partnership in Germany – with the BIH and Charité

Publication date: Dec 02, 2019

The Berlin Institute of Health (BIH) and CharitcE9 – UniversitcE4tsmedizin Berlin are the first institutions in Germany to receive funding to create a translational partnership with the UK-based Wellcome Trust.

Via its translational partnerships, the Wellcome Trust supports institutions in finding new ways to translate biomedical discoveries into novel treatments, technologies and medical devices.

The fact that the BIH and CharitcE9 are among the first institutions in continental Europe to be funded under this scheme underscores their achievements and prominent position in the translational research field.

Fostering a change in research culture The overarching aim of the translational partnership between the Wellcome Trust and the BIH/CharitcE9 is to effect a change in research culture, thus maximizing the possibilities for translational medicine to benefit patients and society at large.

Paving the way for personalized medicine Professor Heyo K. Kroemer, Chairman of the Executive Board of CharitcE9 and BIH Executive Board Member, also expressed his delight about the partnership: -The Wellcome Trust is one of the world’s leading foundations focused on medical research and has so far supported research institutions like the University of Oxford and Cambridge University.

That the BIH and CharitcE9 now belong to the foundation’s translational partnership network reflects the groundbreaking role that our translational research plays in paving the way for innovative personalized healthcare.

As Dean of CharitcE9 and interim Chairman of the BIH Executive Board, Professor Axel Radlach Pries recently attended Wellcome’s Translational Partnerships’ Annual Meeting in London.

Funded to 90 percent by the Federal Ministry of Education and Research (BMBF) and ten percent by the State of Berlin, its founding institutions are CharitcE9 – UniversitcE4tsmedizin Berlin and the Max DelbrcFCck Center for Molecular Medicine in the Helmholtz Association (MDC), both of which serve as independent member bodies.

Concepts Keywords
Berlin Inquiry
Berlin Senator Medical research
Biomedical Translational research
BMBF Wellcome Trust
Caddick Translational medicine
Cambridge University Research
Cas9 Knowledge
Chairman Executive Health
Clinical Trial Therapies progressive disease
Continental Europe Personalized healthcare partnership
CRISPR Healthcare solutions
Ecosystem
Epidemic
Genetically Engineered
Germany
Governing Mayor
Healthcare
Helmholtz
Immune Cells
Immunology
London
MDC
Oxford
Precision Medicine
Progressive
Society
Translational Medicine
Treg Cells
Wellcome Trust

Semantics

Type Source Name
pathway REACTOME Translation
drug DRUGBANK Huperzine B
drug DRUGBANK Tropicamide
disease MESH infections
disease MESH development
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK BK-MDA

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *